Table Of Content

Breast Cancer Research and Treatment 25: 287-286, 1993. © 1993 Kluwer Academic Publishers. Printed in the Netherlands. Author index, Volume 25 Allasia C 203 Filice A 193 Maas MJ 11 Andrac L 203 Filmer A 217 MacDonald NJ 175 Fintor L 113 Magarian RA 225 Bailes JS 119 Flatow U 175 Marth C 47 Bar-Deroma R 211 Frittitta L 73 Mehta RR 65 Bastert G 37 Merchant TE 257 Baumann KH 37 Gatzmeier W 235 Miiller LC 47 Beex LVAM 21,277 Gibson DFC 141 Miiller-Holzner E 47 Benedict M 175 GoldfineI 73 Neugut AI 211 Benraad ThJ 21 Goldstein D 141 Benson EA 283 Grasso G 73 Nia AH 217 Blank EW 265 Graves JM 65 Nicolson GL 165 Bonnier P 203 Gregory W 247 Borden EC 141 Grutters JC 277 Obertop H 257 Brooks SA 247 Orr FW 151 BrownJ 283 Habif DV Sr 265 Ozzello L 265 Brown ML 113 Hackenberg R 217 Hart GD 65 Papa V 73 Camplejohn RS 247 Hawighorst T 217 Pasqualini JR 29 Cantell K 265 Hermus ARMM 277 Pencil SD 165 Ceriani RL 265 HerrstedtJ 57 Pento JT 225 Charpin C 203 Hillner BE 97 Piana L 203 Chetrite G 29 Collette C 11 Jain PT 225 Rauschecker H 235 Johnson DA 141 Rennert G 211 Daniell HW 193 Jones M 283 Robinson E 211 Dapunt O 47 Jordan VC 141 Rosner D 127 Das Gupta TK 65 Runnebaum B 37 Daxenbichler G 47 Kaufmann M 37 de Graaf PW 257 Kienhuis CBM 21 Sanchez-Sweatman OH Delalonde L 29 Kiesel L 37 151] De La Rosa A_ 175 Kloppenborg PWC 21 Sauerbrei W 235 de Mulder PHM 277 Koenders PG 21 Schapira DV 107 De Rosa CM 265 Kostenuik P 151 Schauer A 235 Desch CE 97 Schmoor C 235 Devictor B 203 Lane WW _ 127 Schulz K-D 217 Dombernowsky P 57 Langan-Fahey SM 141 Schumacher M 235 Dori DL 211 Lavaut M-N 203 Shay JW 83 Leathem AJC 247 Silkaitis A 65 Engelholm SA 57 Leone A 175 Singh G 151 288 Author index Smith TJ 97 Toh Y 165 Vigneri R 73 Steeg PS 175 Trischitta V 73 Stenbygaard LE 57 Wakeling AE 1 Svendsen KR 57 Ummenhofer L 235 Werbin H 83 Wright WE 83 Tam E 193 van der Tweel I 11 Thomsen JF 57 van Noord PAH 11 Ziemet AG 47 Breast Cancer Research and Treatment 25: 289-292, 1993. © 1993 Kluwer Academic Publishers. Printed in the Netherlands. Subject index, Volume 25 adjuvant therapy buserelin (GnRH analogue) cost-effectiveness in early breast cancer 97-105 binding sites in clinical breast cancer specimens age 37-46 prognostic factor in node-negative breast cancer 127-139 calpactin II aging see annexin I senescence vs. immortalization, hypothesis clinical practice 83-94 payment and coverage issues in oncology aminohydroxypropylidene bisphosphonate (APD) 119-126 in treatment of hypercalcemia of breast cancer clinical trials 277-281 and the Medicare fee schedule 119-126 androgen receptor contralateral breast cancer and action of MPA in ER/PR-negative breast follow-up procedures and detection 211-215 cancer cells 217-224 cost analysis annexin I of diagnosis and treatment — mini-symposium association with metastasis 165-174 97-126 antiestrogens cyclopropyl antiestrogen "compound 7a" decision analysis model 225-233 cost-effectiveness of adjuvant therapy 97-105 pure antiestrogens in clinical breast cancer 1-9 differential hybridization resistance overcome by factors from mouse metastasis-associated genes 165-174 fibroblasts 29-35 differentiation toremifene and tamoxifen — cross-over trial and increased nm23 expression in mammary 57-63 gland 175-187 see also tamoxifen comparing components of histologic grade athymic mice 235-245 see nude mice histological, in prognosis 127-139 bilateral breast cancer follow-up procedures and detection of second EF-1a primaries 211-215 association with metastasis 165-174 bisphosphonates EGF receptor aminohydroxypropylidene bisphosphonate in clinical prognostic study 21-27 treatment of hypercalcemia 277-281 immunocytochemical assay and prognostic bone metastases factors 203-210 follow-up after APD in treatment of endocrine therapy hypercalcemia 277-281 MPA action through androgen receptor 217-224 mechanisms for targeting metastatic cells to new pure antiestrogens 1-9 bone 151-163 toremifene / tamoxifen cross-over trial 57-63 290 Subject index, Vol. 25 epidemiology hypercalcemia selenium and postmenopausal breast cancer risk follow-up after APD treatment 277-281 11-19 epidermal growth factor ICI 164,384 see EGF and effects of conditioned media on T-47D cells estrogen receptor 29-35 negative association with EGF receptor 21-27 pure antiestrogen 1-9 ICI 182,780 pure antiestrogen 1-9 fibroblasts conditioned media and breast cancer cell growth image analysis factors 29-35 applied to immunocytochemical assay of EGF receptor 203-210 follow-up, postoperative imaging and detection of second primaries 211-215 MRI in surgical treatment planning 257-264 cost-effectiveness 107-111 immortalization hypothesis involving p53 and telomere end GAP proteins losses 83-94 no association with nm23 metastasis suppression immunoconjugates 182 interferon-G/anti-mucin conjugate for treatment glycosylation 265-276 prognostic abnormality detected by HPA lectin immunohistochemistry binding 247-256 progesterone receptor assay in paraffin sections GnRH binding sites 47-55 in clinical breast cancer specimens 37-46 insulin receptor gonadotropin-releasing hormone structure and function in human breast cancer see GnRH 73-82 grading systems interferon alpha comparing components of histologic grade conjugate with anti-mucin antibody for treatment 235-245 265-276 growth factors interferon beta insulin receptor sensitivity in human breast growth suppression with tamoxifen in MCF-7/ cancer 73-82 nude mouse model 141-150 Helix pomatia \ectin lectin HPA binding binding as a prognostic factor 247-256 as a prognostic factor 247-256 histologic differentiation prognostic factor in node-negative breast cancer magnetic resonance imaging (MRI) 127-139 in surgical treatment planning 257-264 histologic grade mammography pleomorphism as the prognostic component and detection of second primaries 211-215 235-245 comparison with MRI in surgical treatment hormone therapy planning 257-264 see endocrine therapy cost-effectiveness study of screening 113-118 host factors Matrigel influence of smoking and obesity on early tumor in growth of human breast cancers in nude mice behavior 193-201 65-71 Subject index, Vol.25 291 MCF-7 cells tamoxifen/interferon-beta synergism against actions of the cyclopropyl! antiestrogen MCF-7 growth 141-150 compound 7a 225-233 tamoxifen/interferon-beta synergism in nude obesity mouse model 141-150 and larger axillary metastases 193-201 MDA-MB-231 cells off-label drug uses effects of factors from mouse fibroblasts 29-35 and the Medicare fee schedule 119-126 medical resource allocation osteolysis cost-effectiveness of screening, adjuvant therapy, and release of growth factors in bone metastasis and postoperative surveillance 97-126 151-163 medroxyprogesterone acetate (MPA) action through androgen receptor 217-224 p53 metastasis in immortalization model 83-94 associated genes by differential hybridization paracrine interactions 165-174 factors in fibroblast conditioned media 29-35 mechanisms and genes — mini-symposium pleomorphism 151-187 the prognostic component of histologic grade nude mouse model for human breast cancers 235-245 65-71 postoperative follow-up suppression by nm23 gene expression 175-187 cost-effectiveness 107-111 MFM-223 human breast cancer cells progesterone receptor action of MPA via androgen receptor 217-224 immunohistochemical assay parameters in microenvironment paraffin sections 47-55 and model for bone metastasis 151-163 reduced in metastatic lymph nodes 47-55 mini-symposia progestins cost analysis of diagnosis and treatment 97-126 MPA action through androgen receptor 217-224 metastases, from genome to therapy 151-187 prognostic factors mitogen-activated protein kinases (MAPKs) EGF receptor 21-27 ERK2 association with metastasis 165-174 EGF receptor vs. other factors 203-210 mitotic index lectin HPA binding and nodal metastases comparing components of histologic grade 247-256 235-245 Nottingham Index (letter) 283 mucin pleomorphism as the prognostic component of Mc5 anti-mucin/interferon-a conjugate for histologic grade 235-245 treatment 265-276 tumor size, histologic differentiation, and age in node-negative breast cancer 127-139 nm23 quality of life and suppression of metastasis 175-187 in cost-effectiveness study of adjuvant therapy Nolvadex 97-105 see tamoxifen nucleoside diphosphate kinase rat mammary carcinoma 13762NF activity of nm23 gene product 175-187 metastatic sublines and metastasis-associated nude mice genes 165-174 model for growth and metastasis of human Rb breast cancers 65-71 in immortalization model 83-94 292 Subject index, Vol. 25 recurrence resistance mechanisms 6-7 cost-effective strategy for detection 107-111 see also antiestrogens risk groups telomere ends in node-negative breast cancer 127-139 loss in immortalization model 83-94 TGF-B screening and bone metastasis model 151-163 cost-effectiveness study 113-118 toremifene selenium cross-over clinical trial with tamoxifen 57-63 and breast cancer risk 11-19 transforming growth factor senescence see TGF control by telomere end losses, hypothesis tumor size 83-94 prognostic factor in node-negative breast cancer smoking 127-139 and larger axillary metastases 193-201 tumor suppressor genes surveillance see nm23, p53, Rb cost-effective strategy for detecting recurrence tyrosine kinase 107-111 insulin sensitivity in human breast cancer 73-82 T-47D cells effects of factors from mouse fibroblasts 29-35 Walker 256 rat cells tamoxifen and model for bone metastasis 151-163 comparison with new pure antiestrogens 1-9 cross-over clinical trial with toremifene 57-63 xenografts enhanced growth suppression by interferon-beta use of Matrigel for human breast cancers in in MCF-7/nude mouse model 141-150 nude mice 65-71